Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) started to evolve from cluster of cases to spread around the world causing the Coronavirus disease 2019 (COVID-19) pandemic. By the end of 2020 U.S. Food and Drug approved Pfizer-BioNTech (COMIRNATY) as one of the first approved vaccine and it utilizes messenger RNA (mRNA) to triggers an immune response to mitigate the actual infection effect. The reported common side effects such as mild local pain at the site of injection, headache, muscle ache, joint pain, and fever. Herein, we report the two cases from Saudi Arabia, who were diagnosed as having Guillain-Barre syndrome post COVID-19 vaccination. The two patients presented to the Emergency Room of the Security Forces Hospital Program with chief complain of weakness which started by affecting their lower limbs bilaterally followed by both upper limb weakness. The patients were satisfying the clinical criteria of Guillain-Barré syndrome. One of the patients was having reduced vital capacity and was unable to clear his secretion so intubation was made to protect the airway. The patients were started on Intravenous immunoglobulins 0.4 g/kg infusion daily for five days. They were also started on sessions of physiotherapy. The patient's condition improved markedly and rapidly after receiving the IV immunoglobulins It is critically important for health care workers to rapidly recognize neurological complications and other side effects associated with COVID-19 vaccination.
| Published in | International Journal of Infectious Diseases and Therapy (Volume 7, Issue 1) |
| DOI | 10.11648/j.ijidt.20220701.12 |
| Page(s) | 8-12 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Guillain-Barre Syndrome, mRNA, Saudi Arabia, COVID-19, Pfizer-BioNTech, Pandemic, Vaccination
| [1] | Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061-1069. Doi: 10.1001/jama.2020.1585. |
| [2] | Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19 (3): 141-154. doi: 10.1038/s41579-020-00459-7. |
| [3] | Pfizer-BioNTech COVID-19 Vaccine. US food & drug administration website. U.S. Food & Drug Administration. Accessed November 28, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-COVID-19/pfizer-biontech-COVID-19-vaccine%0A. |
| [4] | Khan F, Sharma P, Pandey S, et al. COVID-19-associated Guillain-Barre syndrome: Postinfectious alone or neuroinvasive too? J Med Virol. 2021; 93 (10): 6045-6049. doi: 10.1002/jmv.27159. |
| [5] | Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019; 15 (11): 671-683. doi: 10.1038/s41582-019-0250-9. |
| [6] | Benamer HTS, Bredan A. Guillain-Barré syndrome in Arab countries: a systematic review. J Neurol Sci. 2014; 343 (1-2): 221-223. doi: 10.1016/j.jns.2014.05.065. |
| [7] | Alanazy MH, Bakry SS, Alqahtani A, et al. Clinical features and outcome of Guillain-Barre syndrome in Saudi Arabia: a multicenter, retrospective study. BMC Neurol. 2021; 21 (1): 275. doi: 10.1186/s12883-021-02314-5. |
| [8] | Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet (London, England). 2016; 388 (10045): 717-727. doi: 10.1016/S0140-6736(16)00339-1. |
| [9] | Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis. 2001; 1 (1): 29-37. doi: 10.1016/S1473-3099(01)00019-6. |
| [10] | Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet (London, England). 2005; 366 (9497): 1653-1666. doi: 10.1016/S0140-6736(05)67665-9. |
| [11] | Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 1979; 110 (2): 105-123. doi: 10.1093/oxfordjournals.aje.a112795. |
| [12] | Chen Y, Zhang J, Chu X, Xu Y, Ma F. Vaccines and the risk of Guillain-Barré syndrome. Eur J Epidemiol. 2020; 35 (4): 363-370. doi: 10.1007/s10654-019-00596-1. |
| [13] | Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. Published online 2021. doi: 10.1038/s41591-021-01556-7. |
| [14] | Shapiro Ben David S, Potasman I, Rahamim-Cohen D. Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2. JAMA Neurol. 2021; 78 (11): 1409-1411. doi: 10.1001/jamaneurol.2021.3287. |
| [15] | Shao S-C, Wang C-H, Chang K-C, Hung M-J, Chen H-Y, Liao S-C. Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerg Infect Dis. 2021; 27 (12): 3175-3178. doi: 10.3201/eid2712.211634. |
| [16] | Osowicki J, Morgan H, Harris A, Crawford NW, Buttery JP, Kiers L. Guillain-Barré Syndrome in an Australian State Using Both mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines. Ann Neurol. 2021; 90 (5): 856-858. doi: https://doi.org/10.1002/ana.26218. |
| [17] | Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf. 2009; 32 (4): 309-323. doi: 10.2165/00002018-200932040-00005. |
| [18] | Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus. 2021; 13 (2): e13426-e13426. doi: 10.7759/cureus.13426. |
| [19] | Rao SJ, Khurana S, Murthy G, Dawson ET, Jazebi N, Haas CJ. A case of Guillain-Barre syndrome following Pfizer COVID-19 vaccine. J community Hosp Intern Med Perspect. 2021; 11 (5): 597-600. doi: 10.1080/20009666.2021.1954284. |
APA Style
Abdulrahman Nasiri, Qais Haddad, Naael Alazwary, Ibrahim Ghozzi, Mohamed Elkarouri. (2022). Guillain-Barre Syndrome Post COVID-19 Vaccination: Case Report. International Journal of Infectious Diseases and Therapy, 7(1), 8-12. https://doi.org/10.11648/j.ijidt.20220701.12
ACS Style
Abdulrahman Nasiri; Qais Haddad; Naael Alazwary; Ibrahim Ghozzi; Mohamed Elkarouri. Guillain-Barre Syndrome Post COVID-19 Vaccination: Case Report. Int. J. Infect. Dis. Ther. 2022, 7(1), 8-12. doi: 10.11648/j.ijidt.20220701.12
AMA Style
Abdulrahman Nasiri, Qais Haddad, Naael Alazwary, Ibrahim Ghozzi, Mohamed Elkarouri. Guillain-Barre Syndrome Post COVID-19 Vaccination: Case Report. Int J Infect Dis Ther. 2022;7(1):8-12. doi: 10.11648/j.ijidt.20220701.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijidt.20220701.12,
author = {Abdulrahman Nasiri and Qais Haddad and Naael Alazwary and Ibrahim Ghozzi and Mohamed Elkarouri},
title = {Guillain-Barre Syndrome Post COVID-19 Vaccination: Case Report},
journal = {International Journal of Infectious Diseases and Therapy},
volume = {7},
number = {1},
pages = {8-12},
doi = {10.11648/j.ijidt.20220701.12},
url = {https://doi.org/10.11648/j.ijidt.20220701.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijidt.20220701.12},
abstract = {Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) started to evolve from cluster of cases to spread around the world causing the Coronavirus disease 2019 (COVID-19) pandemic. By the end of 2020 U.S. Food and Drug approved Pfizer-BioNTech (COMIRNATY) as one of the first approved vaccine and it utilizes messenger RNA (mRNA) to triggers an immune response to mitigate the actual infection effect. The reported common side effects such as mild local pain at the site of injection, headache, muscle ache, joint pain, and fever. Herein, we report the two cases from Saudi Arabia, who were diagnosed as having Guillain-Barre syndrome post COVID-19 vaccination. The two patients presented to the Emergency Room of the Security Forces Hospital Program with chief complain of weakness which started by affecting their lower limbs bilaterally followed by both upper limb weakness. The patients were satisfying the clinical criteria of Guillain-Barré syndrome. One of the patients was having reduced vital capacity and was unable to clear his secretion so intubation was made to protect the airway. The patients were started on Intravenous immunoglobulins 0.4 g/kg infusion daily for five days. They were also started on sessions of physiotherapy. The patient's condition improved markedly and rapidly after receiving the IV immunoglobulins It is critically important for health care workers to rapidly recognize neurological complications and other side effects associated with COVID-19 vaccination.},
year = {2022}
}
TY - JOUR T1 - Guillain-Barre Syndrome Post COVID-19 Vaccination: Case Report AU - Abdulrahman Nasiri AU - Qais Haddad AU - Naael Alazwary AU - Ibrahim Ghozzi AU - Mohamed Elkarouri Y1 - 2022/02/25 PY - 2022 N1 - https://doi.org/10.11648/j.ijidt.20220701.12 DO - 10.11648/j.ijidt.20220701.12 T2 - International Journal of Infectious Diseases and Therapy JF - International Journal of Infectious Diseases and Therapy JO - International Journal of Infectious Diseases and Therapy SP - 8 EP - 12 PB - Science Publishing Group SN - 2578-966X UR - https://doi.org/10.11648/j.ijidt.20220701.12 AB - Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) started to evolve from cluster of cases to spread around the world causing the Coronavirus disease 2019 (COVID-19) pandemic. By the end of 2020 U.S. Food and Drug approved Pfizer-BioNTech (COMIRNATY) as one of the first approved vaccine and it utilizes messenger RNA (mRNA) to triggers an immune response to mitigate the actual infection effect. The reported common side effects such as mild local pain at the site of injection, headache, muscle ache, joint pain, and fever. Herein, we report the two cases from Saudi Arabia, who were diagnosed as having Guillain-Barre syndrome post COVID-19 vaccination. The two patients presented to the Emergency Room of the Security Forces Hospital Program with chief complain of weakness which started by affecting their lower limbs bilaterally followed by both upper limb weakness. The patients were satisfying the clinical criteria of Guillain-Barré syndrome. One of the patients was having reduced vital capacity and was unable to clear his secretion so intubation was made to protect the airway. The patients were started on Intravenous immunoglobulins 0.4 g/kg infusion daily for five days. They were also started on sessions of physiotherapy. The patient's condition improved markedly and rapidly after receiving the IV immunoglobulins It is critically important for health care workers to rapidly recognize neurological complications and other side effects associated with COVID-19 vaccination. VL - 7 IS - 1 ER -
Email: